Global Markets Direct's, 'Melanocortin Receptor 4 (MC4-R or MC4R) - Pipeline Review, H1 2016', provides in depth analysis on Melanocortin Receptor 4 (MC4-R or MC4R) targeted pipeline therapeutics.
The report provides comprehensive information on the Melanocortin Receptor 4 (MC4-R or MC4R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
* The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4-R or MC4R)
* The report reviews Melanocortin Receptor 4 (MC4-R or MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
AgRP is among the most potent and long-lasting appetite stimulators and exerts its effects primarily by opposing the anorexigenic/catabolic actions of POMC by competitively inhibiting melanocortin receptors (specifically MC3-R and MC4-R) at the postsynaptic level.
[alpha]-MSH binds to hypothalamic neurons that express MC4-R, leading to appetite suppression (23).
The hypothalamic melanocortin system, which comprises the MC4-R, its agonist [alpha]-MSH, and its antagonist AgRP, is considered to be the main central anorexigenic pathway controlling energy homeostasis (24).
Variations in AgRP could be due to suppression of MC4-R, leading to a decreased feeding signal and thereby increasing the risk of developing anorexia nervosa.